AdamJacobSchoenfeldMD

PubMed

• Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
  Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, Xinan Wang, Alessio Cortellini, Victor R Vaz, Giuseppe Lamberti, Rosa L Frias, Deepti Venkatraman, Claudia A M Fulgenz...> ;Journal of Thoracic Oncology. 2023 Feb 10
• Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Che...
  Emily S Lebow, Annemarie Shepherd, Jordan E Eichholz, Michael Offin, Daphna Y Gelblum, Abraham J Wu, Charles B Simone 2nd, Adam J Schoenfeld, David R Jones, Andreas Ri...> ;JAMA Network Open. 2023 Jan 3
• 12 citations
  Non-viral precision T cell receptor replacement for personalized cell therapy.
  Susan P Foy, Kyle Jacoby, Daniela A Bota, Theresa Hunter, Zheng Pan, Eric Stawiski, Yan Ma, William Lu, Songming Peng, Clifford L Wang, Benjamin Yuen, Olivier Dalmas, ...> ;Nature. 2022 Nov 10
• 4 citations
  Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
  Ziad Bakouny, Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati, Chih-Yuan Hsu, Saif I Alimohamed, Babar Bashir, Stephanie Berg, Mehmet A Bilen, Daniel Bowles, C...> ;JAMA Oncology. 2023 Jan 1
• 3 citations
  Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
  Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Ad...> ;Journal of Clinical Oncology. 2023 Feb 20
• 6 citations
  Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
  Amin H Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W Akl, Pier Vitale Nuzzo, Tarek H Mouhieddine, Tomin Perea-Chamblee, Kodi Taraszka, Hab...> ;Cancer Cell. 2022 Oct 10
• Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
  Kamrine E Poels, Adam J Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O McDonald, Weiwei ...> ;Nature Communications. 2022 Sep 23
• SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Recepto...
  Hiroki Sato, Daisuke Kubota, Huan Qiao, Achim Jungbluth, Natasha Rekhtman, Adam J Schoenfeld, Helena A Yu, Gregory J Riely, Shinichi Toyooka, Christine M Lovly, Paul P...> ;JCO Precision Oncology. 2022 Aug 1
• 4 citations
  Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS-mutated non-small-cell lung cancer.
  B Ricciuti, J V Alessi, A Elkrief, X Wang, A Cortellini, Y Y Li, V R Vaz, H Gupta, F Pecci, A Barrichello, G Lamberti, T Nguyen, J Lindsay, B Sharma, K Felt, S J Rodig...> ;Annals of Oncology. 2022 Oct 1
• 2 citations
  Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer.
  Adam J Schoenfeld, Hira A Rizvi, Danish Memon, Narek Shaverdian, Matthew J Bott, Jennifer L Sauter, C Jillian Tsai, Jayon Lihm, David Hoyos, Andrew J Plodkowski, Rocio...> ;Clinical Cancer Research. 2022 Sep 1
• 2 citations
  Deciphering radiological stable disease to immune checkpoint inhibitors.
  J Luo, S Wu, H Rizvi, Q Zhang, J V Egger, J C Osorio, A J Schoenfeld, A J Plodkowski, M S Ginsberg, M K Callahan, C Maher, A N Shoushtari, M A Postow, M H Voss, R R Ko...> ;Annals of Oncology. 2022 Aug 1
• 1 citations
  MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
  Sudarshan R Iyer, Igor Odintsov, Adam J Schoenfeld, Evan Siau, Marissa S Mattar, Elisa de Stanchina, Inna Khodos, Alexander Drilon, Gregory J Riely, Marc Ladanyi, Rome...> ;Molecular Cancer Research. 2022 May 4
• 12 citations
  SMARCA4 inactivation promotes lineage-specific transformation and early metastatic features in the lung.
  Carla P. Concepcion, Sai Ma, Lindsay M. LaFave, Arjun Bhutkar, Manyuan Liu, Lydia P. DeAngelo, Jonathan Y. Kim, Isabella Del Priore, Adam J. Schoenfeld, Manon Miller, ...> ;Cancer Discovery. 2021 Sep 24
• 6 citations
  Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
  Kamrine E. Poels, Adam J. Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Tom O. McDonald, Weiwei ...> ;2011 Conference on Lasers and Electro-Optics Europe and 12th European Quantum Electronics Conference. 2021 Jun 17
• 24 citations
  Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer
  Jessica J. Lin, Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, Ted William Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Charlotte E. Lee, Andre...> ;Clinical Cancer Research. 2021 May 15
• 27 citations
  Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
  Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc ...> ;Clinical Cancer Research. 2021 Mar 8
• 1 citations
  How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?
  Adam J. Schoenfeld, Roisin E O'Cearbhaill> ;Cancer Journal. 2021 Mar 1
• 11 citations
  Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
  Jason Beattie, Hira Rizvi, Paige Fuentes, Jia Luo, Adam J. Schoenfeld, I-Hsin Lin, Michael A. Postow, Margaret K. Callahan, Martin H. Voss, Neil J. Shah, Allison Betof...> ;Journal for ImmunoTherapy of Cancer. 2021 Feb 1
• 60 citations
  ROS1-dependent cancers - biology, diagnostics and therapeutics.
  Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam J. Schoenfeld, Clare Keddy, Monika A. Davare> ;Nature Reviews Clinical Oncology. 2021 Jan 1
• 1 citations
  Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers-Reply.
  Adam J. Schoenfeld, Helena A. Yu> ;JAMA Oncology. 2020 Dec 1
• 54 citations
  The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
  Adam J. Schoenfeld, Chaitanya Bandlamudi, Jessica A. Lavery, Joseph Montecalvo, Azadeh Namakydoust, Hira Rizvi, Jacklynn V. Egger, Carla P. Concepcion, Sonal Paul, Mar...> ;Clinical Cancer Research. 2020 Nov 1
• 65 citations
  Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
  Helena A. Yu, Adam J. Schoenfeld, Alex Makhnin, Rachel Kim, Hira Rizvi, Dana W.Y. Tsui, Christina Falcon, Brian Houck-Loomis, Fanli Meng, Julie Li Yang, Yosef Tobi, Gl...> ;JAMA Oncology. 2020 Jul 1
• 124 citations
  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
  Adam J. Schoenfeld, Joseph M. Chan, Daisuke Kubota, Hiroki Sato, Hira Rizvi, Yahya Daneshbod, Jason C. Chang, Paul K. Paik, Michael Offin, Maria E. Arcila, Monika A. D...> ;Clinical Cancer Research. 2020 Jun 1
• 114 citations
  Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
  Adam J. Schoenfeld, Hira Rizvi, Chaitanya Bandlamudi, Jennifer L. Sauter, William D. Travis, Natasha Rekhtman, Andrew J. Plodkowski, Rocio Perez-Johnston, Peter Sawan,...> ;Annals of Oncology. 2020 May 1
• 222 citations
  Acquired Resistance to Immune Checkpoint Inhibitors.
  Adam J. Schoenfeld, Matthew D. Hellmann> ;Cancer Cell. 2020 Apr 13
• Join now to see all

Journal Articles

• Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers  
  Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
• Synthesis, Structure, Dynamics, and Selective Methylation of Platinum and Palladium Diphosphametallacyclobutane Complexes  
  Chapp TW, Schoenfeld A, Sanderson MD, Chang C, Glueck DS, Golen J, Moore C, Rheingold A, Organometallics, 2012
• Effects of Linker Length on the Rate and Selectivity of Platinum-Catalyzed Asymmetric Alkylation of the Bis(isitylphosphino)alkanes IsHP(CH2)nPHIs (is = 2,4,6-(i-pr)3C...  
  Chapp TW, Schoenfeld A, Glueck DS, Organometallics, 2010

Abstracts/Posters

• The CNS Germinoma Experience at UCSF from 1980 to 2010
  Schoenfeld A, Molinaro A, Banerjee A, Haas-Kogan D, Mueller S, 3rd International CNS Germ Cell Tumour Symposium, Cambridge, England, 2013

Lectures

• Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers. 
  2019 ASCO Annual Meeting - 6/1/2019